| pubmed-article:3894586 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C1704247 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C0029925 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C0008838 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C0010711 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C0281548 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C1314939 | lld:lifeskim |
| pubmed-article:3894586 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:3894586 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:3894586 | pubmed:dateCreated | 1985-8-26 | lld:pubmed |
| pubmed-article:3894586 | pubmed:abstractText | Sixty-two patients with refractory ovarian carcinoma or other malignancies principally confined to the peritoneal cavity were treated with an intraperitoneal combination chemotherapy regimen consisting of cisplatin (100 mg/m2 or 200 mg/m2) and cytosine arabinoside (4 X 10(-3) mol/L or 10(-2) mol/L). Sodium thiosulfate was simultaneously administered intravenously (IV) to protect against cisplatin-induced nephrotoxicity. Sixteen of 52 evaluable patients demonstrated evidence of a clinical response including 14 (36%) of 39 with refractory ovarian carcinoma. Systemic toxicity was not severe except for cisplatin-induced emesis and a single episode of major renal insufficiency. Dose-limiting toxicity was bone marrow suppression with cytosine arabinoside administered at 10(-2) mol/L. We conclude that combination intraperitoneal therapy with high-dose cisplatin and cytosine arbinoside can be safely administered with objective tumor responses observed in patients with ovarian carcinoma refractory to front-line chemotherapy and in occassional individuals with other malignancies principally confined to the peritoneal cavity. | lld:pubmed |
| pubmed-article:3894586 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3894586 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3894586 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3894586 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3894586 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3894586 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3894586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3894586 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3894586 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3894586 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:3894586 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:3894586 | pubmed:author | pubmed-author:LucasW EWE | lld:pubmed |
| pubmed-article:3894586 | pubmed:author | pubmed-author:HowellS BSB | lld:pubmed |
| pubmed-article:3894586 | pubmed:author | pubmed-author:MarkmanMM | lld:pubmed |
| pubmed-article:3894586 | pubmed:author | pubmed-author:ClearySS | lld:pubmed |
| pubmed-article:3894586 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3894586 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:3894586 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3894586 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3894586 | pubmed:pagination | 925-31 | lld:pubmed |
| pubmed-article:3894586 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:meshHeading | pubmed-meshheading:3894586-... | lld:pubmed |
| pubmed-article:3894586 | pubmed:year | 1985 | lld:pubmed |
| pubmed-article:3894586 | pubmed:articleTitle | Intraperitoneal chemotherapy with high-dose cisplatin and cytosine arabinoside for refractory ovarian carcinoma and other malignancies principally involving the peritoneal cavity. | lld:pubmed |
| pubmed-article:3894586 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:3894586 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:3894586 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:3894586 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3894586 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:3894586 | lld:pubmed |
